Plymouth Meeting-based Inovio teams up with AIDS Malignancy Consortium for immunotherapy study
Inovio Pharmaceuticals, Inc. has entered into a partnership with the AIDS Malignancy Consortium to evaluate VGX-3100 as a potential therapy for HIV-positive adult men and women.
The Plymouth Meeting, Pa., biopharmaceutical company is developing VGX-3100, an immunotherapy designed to boost the ability of person's immune system to fight diseases, as a treatment for human papillomavirus (HPV)-associated precancerous conditions.
Under the terms of the partnership, the consor tium will fund a mid-stageā¦
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Cancer & Oncology | Genital Warts | Health Management | HIV AIDS | Human Papillomavirus (HPV) | Immunotherapy | Partnerships | Pharmaceuticals | Study | Women